Cell & Gene Therapy

1. SKyvec™ Lenti For In Vivo Applications 10/7/2026

   When lentiviral vector moves from ex vivo intermediate to in vivo final drug product, purity, potency, and consistency expectations rise, and downstream capture performance becomes a central constraint.

2. Simplifying Adenoviral Purification For Scalable Manufacturing 10/7/2026

   As vector design advances, downstream purification limits adenoviral manufacturing. A membrane-integrated hybrid train reduces product loss and process complexity at scale.

3. Crude Peptide Purification Optimization For Scalable Manufacturing 10/7/2026

   Transitioning lentiviral vectors to final drug product raises quality demands. A simplified membrane-based capture step minimizes downstream losses that can constrain systemic dosing.

4. GLP-1 Peptides In Asia: Expanding Access And Opportunity 9/17/2026

   Asia's growing role in the GLP-1 market presents new opportunities and challenges. Learn how regulatory preparedness, scalable manufacturing, and robust quality systems can enable growth.

5. Viral Vector Services 9/15/2026

   Fast-track your Gene Therapies from cutting-edge process development to commercial success with advanced viral vector manufacturing solutions!

6. GLP-1 Peptides Around The World Part III: EU Evolution – Expanded Expectations And Emerging Enforcement 9/15/2026

   Navigating GLP-1 development in Europe? Discover how stricter CMC, Annex 1, serialization, and supply chain requirements are influencing manufacturing strategies.

7. SK Pharmteco Capabilities Update July 2026: Gene Therapy 8/3/2026

   Adaptive viral vector platforms pair scalable manufacturing with targeted purification. Customizing workflows ensures high vector purity and cost efficiency, accelerating clinical development.

8. Solving Challenges For Vectors That Are Complex In Practice 7/8/2026

   Overcome adenoviral scale-up challenges with a design-to-scale manufacturing framework that optimizes cell growth, boosts vector productivity, and supports reliable clinical supply.

9. Maximizing Efficiency In Lentiviral Vector Manufacturing 7/8/2026

   Accelerate cell and gene therapy programs with scalable lentiviral vector manufacturing, delivering high titers, exceptional purity, and reliable clinical supply from gene to clinic.

10. Optimizing Adenoviral Production With Adaptive Process Architecture 7/8/2026

    Speed adenoviral vector development with scalable suspension processes and hybrid purification workflows that improve yield, efficiency, and clinical readiness.